113 related articles for article (PubMed ID: 9665036)
1. Regulation of alloreactivity in the popliteal lymph node assay by the new immunosuppressants: malononitrilamides.
Schorlemmer HU; Ruuth E; Kurrle R
Transpl Int; 1998; 11 Suppl 1():S448-51. PubMed ID: 9665036
[TBL] [Abstract][Full Text] [Related]
2. The alloreactivity in the popliteal lymph node (PLN) assay is regulated by malononitrilamides (MNAs).
Schorlemmer HU; Ruuth E; Kurrle R
Int J Tissue React; 1997; 19(3-4):157-61. PubMed ID: 9506317
[TBL] [Abstract][Full Text] [Related]
3. The new immunosuppressants, the malononitrilamides MNA 279 and MNA 715, inhibit various graft-vs.-host diseases (GvHD) in rodents.
Schorlemmer HU; Kurrle R; Bartlett RR
Drugs Exp Clin Res; 1997; 23(5-6):167-73. PubMed ID: 9515226
[TBL] [Abstract][Full Text] [Related]
4. Malononitrilamides synergistically prevent acute and treat ongoing skin allograft rejection with cyclosporine.
Schorlemmer HU; Ruuth E; Kurrle R
Transpl Int; 1998; 11 Suppl 1():S340-4. PubMed ID: 9665012
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of alloreactivity in the popliteal lymph node assay by malononitrilamides.
Schorlemmer HU; Bartlett RR; Kurrle R
Transplant Proc; 1998 Jun; 30(4):968-70. PubMed ID: 9636391
[No Abstract] [Full Text] [Related]
6. Synergistic activity of malononitrilamides with cyclosporine to control and reverse xenograft rejection.
Schorlemmer HU; Kurrle R
Int J Tissue React; 1997; 19(3-4):149-56. PubMed ID: 9506316
[TBL] [Abstract][Full Text] [Related]
7. Various graft vs. host diseases (GvHD) in rodents can be prevented and treated by malononitrilamides (MNAs).
Schorlemmer HU; Kurrle R; Bartlett RR
Inflamm Res; 1997 Aug; 46 Suppl 2():S165-6. PubMed ID: 9297563
[No Abstract] [Full Text] [Related]
8. Analogues of leflunomide's primary metabolite, the malononitrilamides, prevent the development of graft-versus-host disease.
Schorlemmer HU; Bartlett RR; Kurrle R
Transplant Proc; 1997; 29(1-2):1298-301. PubMed ID: 9123315
[No Abstract] [Full Text] [Related]
9. Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat.
Bilolo KK; Ouyang J; Wang X; Zhu S; Jiang W; Qi S; Xu D; Hebert MJ; Bekersky I; Fitzsimmons WE; Chen H
Transplantation; 2003 Jun; 75(11):1881-7. PubMed ID: 12811249
[TBL] [Abstract][Full Text] [Related]
10. Malononitrilamides 715 and 279 prevent accelerated cardiac allograft rejection synergistically with cyclosporin A in presensitized rats.
Qi Z; Simanaitis M; Ekberg H
Transpl Immunol; 1998 Jun; 6(2):94-100. PubMed ID: 9777697
[TBL] [Abstract][Full Text] [Related]
11. Malononitrilamides 715 and 279 prolong rat cardiac allograft survival, reverse ongoing rejection, inhibit allospecific antibody production and interact positively with cyclosporin.
Qi Z; Ekberg H
Scand J Immunol; 1998 Oct; 48(4):379-88. PubMed ID: 9790308
[TBL] [Abstract][Full Text] [Related]
12. In vivo lymphoproliferation in the popliteal lymph node (PLN) assay can be inhibited by leflunomide's active metabolite A77 1726.
Schorlemmer HU; Kurrle R; Schleyerbach R; Bartlett RR
Inflamm Res; 1999 Dec; 48 Suppl 2():S111-2. PubMed ID: 10667839
[No Abstract] [Full Text] [Related]
13. Therapeutic activity of malononitrilamides (MNA 279 and MNA 715) on acute and chronic, relapsing, experimental, allergic encephalomyelitis (EAE).
Schorlemmer HU; Bartlett RR
Drugs Exp Clin Res; 1997; 23(5-6):175-81. PubMed ID: 9515227
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay.
Slauson SD; Silva HT; Sherwood SW; Morris RE
Immunol Lett; 1999 Apr; 67(3):179-83. PubMed ID: 10369124
[TBL] [Abstract][Full Text] [Related]
15. Synergism of the malononitrilamides 279 and 715 with cyclosporine A in the induction of long-term cardiac allograft survival.
Lindner JK; Zantl N
Transpl Int; 1998; 11 Suppl 1():S303-9. PubMed ID: 9665002
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of restenosis development after mechanical injury: a new field of application for malononitrilamides?
Schrepfer S; Deuse T; Sultan KR; Haddad M; Böger R; Münzel T; Schäfer H; Pelletier MP; Robbins RC; Reichenspurner H
Cardiology; 2007; 108(2):128-37. PubMed ID: 17028423
[TBL] [Abstract][Full Text] [Related]
17. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. IV. Examination of T cell subsets in graft-versus-host assays.
Pearce NW; Dorsch SE; Hall BM
Transplantation; 1990 Sep; 50(3):493-7. PubMed ID: 1976283
[TBL] [Abstract][Full Text] [Related]
18. Leflunomide prolongs pulmonary allograft and xenograft survival.
Yuh DD; Gandy KL; Morris RE; Hoyt G; Gutierrez J; Reitz BA; Robbins RC
J Heart Lung Transplant; 1995; 14(6 Pt 1):1136-44. PubMed ID: 8719461
[TBL] [Abstract][Full Text] [Related]
19. The antiproliferative effect of malononitrilamides (MNAs) on vascular smooth muscle cells is antagonized by exogenous uridine.
Czech J; Kurrle R; Schorlemmer HU
Inflamm Res; 1999 Dec; 48 Suppl 2():S128-9. PubMed ID: 10667848
[No Abstract] [Full Text] [Related]
20. Hyperacute skin allograft rejection in presensitized rats is abrogated by malononitrilamides.
Schorlemmer HU; Kurrle R
Transplant Proc; 1998 Jun; 30(4):963-7. PubMed ID: 9636390
[No Abstract] [Full Text] [Related]
[Next] [New Search]
